Rezolute Reports Strong Interim Phase 3 Data for Ersodetug in Tumor Hyperinsulinism
Summary
Rezolute reported positive interim data from its Phase 3 upLIFT study for ersodetug in tumor hyperinsulinism, with 6 of 8 participants meeting the primary endpoint and discontinuing IV glucose.
Key Events
-
Positive Interim Phase 3 Results
The upLIFT study for ersodetug in tumor hyperinsulinism showed 6 of 8 participants met the primary endpoint, achieving at least a 50% reduction in intravenous glucose requirements, with all 6 completely discontinuing IV glucose.
-
Study Enrollment Update
The Phase 3 upLIFT study is now 50% enrolled, with 8 of the planned 16 participants recruited.
-
Favorable Safety Profile
Ersodetug has been well-tolerated in both the pivotal and extension phases of the study, with no drug-related adverse events reported to date.
-
Future Milestones
Topline results for the fully enrolled open-label study are expected in the second half of 2026. The company will also continue engagement with the FDA regarding the congenital HI indication.
Analysis
Rezolute announced highly positive interim results from its Phase 3 upLIFT study for ersodetug in tumor hyperinsulinism. Six out of eight enrolled participants met the primary endpoint, achieving at least a 50% reduction in intravenous glucose requirements, with all six completely discontinuing IV glucose. This strong efficacy data for an ultra-rare disease, coupled with a favorable safety profile, significantly de-risks the program and provides a clear path forward for this indication. The company also highlighted how these results validate ersodetug's mechanism, contrasting with previous challenges in the sunRIZE study for congenital HI.
At the time of this filing, RZLT was trading at $3.68 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $347.6M. The 52-week trading range was $1.07 to $11.46. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.